StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BGLC$2.24-0.24%
Fair $2.24+0.0%

BGLC

BioNexus Gene Lab Corp.

Basic Materials / Specialty ChemicalsNasdaqCM

$2.24

-0.01 (-0.24%)

Fairly Valued+0.0%Fair Value $2.24Fund rank 28/100 · Data gapFallback financials|
SA 23/D
F-Score: 3/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-2.0M · quality 54.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 19/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

23/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 8Warnings: 2unknown: 8
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Revenue has declined for 4 consecutive years ROE is -34.6%, below the 5% threshold
Thesis & Journal · BGLCLocal privado en este navegador · BioNexus Gene Lab Corp.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-34.6%

↓

Gross Margin

14.6%

↓

Debt/Equity

0.02

↓
52-Week Range$2
$2$16

TradingView lightweight chart

BGLC price, volumen y niveles de valoración

Último $2.235Periodo -99.2%
Fair value: $2.240

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2018–2025 · 7 años de histórico normalizado

Revenue CAGR

+66.2%

FCF CAGR

—

FCF margin

-25.3%

FCF / Net income

0.63x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.4M · net income $-3.0M · FCF $-1.9M

2018-FY → 2025-FY

Gross margin

14.6%+1.1% pts

Operating margin

-42.5%-70.8% pts

Net margin

-40.2%-52.7% pts

FCF margin

-25.3%+85.2% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
Income Statement
Revenue$7.4M$7.4M$9.5M$9.8M$10.9M$13.4M$11.4M$126955.00$212328.00
Net Income$-3.0M$-3.0M$-1.6M$-2.6M$-355966.00$751571.00$1.1M$-246469.00$26454.00
EBITDA$-2.8M$-2.8M$-1.4M$-2.5M$-185758.00——$-233991.00$100512.00
EPS-1.61-1.61-0.90-1.66-0.46————
Gross Margin14.6%14.6%13.6%13.6%11.5%17.0%15.1%44.0%13.5%
Operating Margin-42.5%-42.5%-20.6%-31.5%-2.7%7.9%11.2%-217.2%28.2%
Net Margin-40.2%-40.2%-16.8%-26.9%-3.3%5.6%9.6%-194.1%12.5%
Balance Sheet
Debt/Equity0.020.020.030.010.01————
Current Ratio6.526.52———————
Cash Flow
Free Cash Flow$-1.9M$-1.9M$-2.3M$-2.0M$497651.00$5999.00$131059.00$-230090.00$-234459.00
Returns
ROE-34.6%-34.6%-19.2%-27.2%-5.3%10.5%16.4%-22.0%1.7%
Valuation
P/B0.480.480.990.8526.20————
Growth & Yield
Revenue Growth-21.9%-21.9%-2.7%-10.6%—17.3%8872.0%-40.2%—
EPS Growth-79.2%-79.2%46.0%-260.9%—————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -39.6%

Total return

-39.6%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.90 → -1.61

Residual

-39.6%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-39.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.